Immunotherapy Pioneer and Serial Biotech Entrepreneur Patrick Baeuerle to Present Compelling Data from Harpoon Therapeutics’ Biotherapeutics Platform at the 2018 European Congress on Biotechnology
Patrick Baeuerle, Ph.D., a pioneer of T cell engaging therapies and executive partner at life sciences venture firm MPM Capital, will give a keynote presentation about next-generation immuno-oncology therapies from Harpoon Therapeutics, Inc. at the upcoming European Congress on Biotechnology (ECB) on Tuesday, July 3 from 10:30 to 11:00 a.m. CEST in Geneva, Switzerland.
Dr. Baeuerle co-founded Harpoon Therapeutics in 2015 with a vision to build an innovative class of T cell engaging therapeutics optimized to achieve superior efficacy in penetrating solid tumors as an “off-the-shelf” T cell therapy. T cell engagers are unique in their ability to redirect lysis independently of T cell receptor (TCR) specificity and recognition of human leukocyte antigen (HLA) / peptide antigen – the loss of which being a frequent mechanism by which cancer cells escape T cell recognition.
His presentation, entitled “TriTAC™: A novel therapy to treat cancer,” will focus on compelling preclinical data from Harpoon’s TriTAC technology that underscores its potential to overcome the limitations and liabilities of existing T cell-engaging antibody therapies.
Supported by investments led by MPM and the UBS Oncology Impact Fund (OIF) managed by MPM, Harpoon Therapeutics anticipates launching two TriTAC programs in the clinic within the year. The company’s lead candidate, HPN424, targets prostate-specific membrane antigen (PSMA) and will be investigated for use in the treatment of patients with prostate cancer. Its second product candidate, HPN536, targets mesothelin and will be investigated for use in the treatment of patients with a variety of solid tumors.
Dr. Baeuerle, an immunologist by training, is known for his role in the development of the first bispecific T cell engager (BiTE) for hematologic malignancies, Blincyto® (blinatumomab), which was approved by the U.S. Food and Drug Administration (FDA) in less than 3 months in 2014 -- the fastest FDA approval for a cancer drug ever. In 2015, he joined MPM and since then has co-founded six companies with MPM and the UBS OIF in his continued pursuit of novel immunotherapies for cancer.
The ECB is the leading congress for academic and industrial biotechnologists in Europe and the flagship biennial event of the European Federation of Biotechnology. For complete details, please visit www.ecb2018.com.
About Harpoon Therapeutics
Harpoon Therapeutics is an immuno-oncology company founded by Patrick Baeuerle, Ph.D., a pioneer in the development of T-cell engaging therapies, and MPM Capital. The company is focused on the discovery and development of novel T cell engaging biologics for the treatment of cancer and other diseases. Harpoon Therapeutics created a novel antibody-based drug discovery platform called TriTAC™ (tri-specific T cell activating construct) to unleash the targeted cell-killing properties of a patient’s own immune system through T cell activation. This approach has been optimized to penetrate tissues and extend serum exposure, and has the potential to address a broad range of cancers, including solid tumors, and immunologic diseases. HPN424, a prostate-specific membrane antigen (PSMA)-targeting TriTAC™ biologic, is in development for the treatment of prostate cancer and is expected to enter a clinical trial in 2018. For more information, please visit www.harpoontx.com.
About MPM Capital
MPM Capital is a venture firm founding and investing in early-stage life sciences companies that seek to cure major diseases by translating scientific innovations into positive clinical outcomes. MPM’s portfolio of companies aims to revolutionize the face of medicine across multiple areas including cancer, neuroscience, metabolic disorders and regenerative medicine. With its experienced and dedicated investment team, executive partners and entrepreneurs, and its medical and scientific advisory board, MPM is powering novel medical breakthroughs that transform patients’ lives. MPM is currently investing from its BV2014 and BV2018 funds. It also invests from the UBS Oncology Impact Fund managed by MPM -- the first-of-its-kind, oncology-only social impact fund that donates a portion of its profits and royalties to cancer research and cancer care. For further information, please visit www.mpmcapital.com.
For MPM Capital
Liz Doherty, +1 617-425-9275
For MPM Capital/UBS Oncology Impact Fund
Kathy Vincent, +1 310-403-8951
For Harpoon Therapeutics
Kinkead Communications, Inc.
Susan Kinkead, +1 415-509-3610
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Alibaba Announces Smart Mobility Initiatives with Partners20.9.2018 07:17 | Pressemelding
Alibaba Group Holding Limited (NYSE: BABA) announced today a series of smart mobility initiatives in partnership with auto brands and technology service providers. The announcement was made during The Cloud Computing Conference, the company’s largest technology showcase, held over four days in Hangzhou, Alibaba’s home base. Partnering with Bosch on Automated Valet Parking Alibaba Cloud, the cloud-computing arm of Alibaba Group, and Bosch, a leading global supplier of technology services, announced plans to introduce Automated Valet Parking (AVP) solutions in China. Both parties will work together to enable the infrastructure-based, driverless parking solution. The technology is powered by software in a cloud and it will offer a fully automated valet parking service in the near future. As part of the cooperation, Bosch will provide its AVP technology, its experience in systems engineering and its IoT competencies. Alibaba Cloud, meanwhile, will share its technologies and its experience
Egon Zehnder and Mobius Executive Leadership Formalize Exclusive Strategic Partnership20.9.2018 06:01 | Pressemelding
Egon Zehnder, the world’s leadership advisory firm, has entered into a formal partnership with Mobius Executive Leadership, the US and Europe-based premier leadership development firm. The partnership combines the firms’ proprietary methods for accelerating the personal and professional development of senior executives and for stimulating an organization’s ability to transform. “Readiness to lead at the top levels in business and society today requires leaders develop a willingness to understand who they are and who they can become so that they can unlock their full potential – and help their organizations unleash their potential as well,” stated Jill Ader, Egon Zehnder’s Chair-Elect and Co-developer of the Executive Breakthrough Program. “Together with Mobius, we have found success in doing that.” Already collaborating for more than four years, the two firms’ new partnership formally combines Egon Zehnder’s deep leadership advisory experience to the world’s most influential leaders an
Twispay Teams up with Blue Air to Expand Digital Payments20.9.2018 06:00 | Pressemelding
Blue Air, the largest Romanian airline by scheduled passengers flown, and Twispay, Swiss-owned European payment processor and FinTech pioneer, today announced the availability of a payment integration partnership that allows a global clientele to complete online payments through Twispay’s payment services. The airline industry is massively time pressured. Airline companies have learned to adapt business and pricing models according to a wide range of wildly fluctuating variables, from sudden shifts in demand and operational costs to erratic weather patterns. Therefore, the reliability and flexibility of a payment processing integration are paramount. The ability to accept online payments quickly, safely, and with ease is crucial to any 21st - century venture, let alone an airline company. “It was essential for us to establish a partnership with a processing services player who understands and can handle a high volume of transactions and air-travel operational particularities. Additiona
Alibaba A.I. Labs Launches Hospitality Robot20.9.2018 04:00 | Pressemelding
The robotics industry is revolutionizing the world, and Alibaba A.I. Labs is raising the stakes in this cutting-edge industry with the announcement of launching service robots for the hospitality sector starting in October. The news was made at The Computing Conference 2018, which is scheduled for four days till September 22 in Hangzhou, China, the site of Alibaba’s headquarters. Alibaba A.I. Labs is the department leading consumer AI product development at Alibaba. Hotels have until now depended entirely on human labor. But the labs' service robot — from delivering meals to taking laundry to guests — demonstrates what guests can expect at hotels in the future. Guests talk to the robot via voice command, touch and hand gesture, and its responses are driven by AliGenie, the software that powers Alibaba A.I. Labs’ smart speaker, Tmall Genie. “We are excited by this tremendous development that is helping us bridge the gap between guest needs and the response time that they expect. Alibaba
Celltrion Signs 'Incubation' Agreement with Emory University for Development of New Drugs for Atherosclerosis20.9.2018 02:03 | Pressemelding
Celltrion, Inc. (KRX:068270) signed an ‘Incubation’ agreement with Emory University in Atlanta to support the research and development of new drug candidates for atherosclerosis. ‘Incubation’ agreement is one of the open innovation measures by which a company provides its internal resources and capabilities, such as research space and facility, manpower and business operation consulting, to an external research institute or startup so as to support the research and ensure autonomy of the research aimed at developing new drugs or next-generation technology on the condition that the company can preferentially discuss commercialization of the research output. Under the agreement, Celltrion will share Celltrion’s accumulated biologics development expertise with Emory University School of Medicine and the Wallace H. Coulter Department of Biomedical Engineering at Emory University and Georgia Institute of Technology, and provide research costs and manufacturing materials of new drug candidat
Rimini Street Obtains Australian Single Touch Payroll Certification19.9.2018 23:00 | Pressemelding
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced it has obtained Single Touch Payroll (STP) certification by the Australian Government’s Australian Taxation Office (ATO) for PeopleSoft Global Payroll and SAP HCM Payroll. The new certification enables Rimini Street’s Australian clients to submit their payroll data via a ‘pay event,’ either on or before pay day, to the ATO. Rimini Street’s tax, legal and regulatory division passed the complex, rigorous qualification process with the first file submission for both PeopleSoft and SAP software products, well ahead of the deadline set by the ATO. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180919005857/en/ Rimini Street Obtains Australian Single Touch Payroll Certification (Photo: Business Wire) Premium Service Support for Critica